PROGNOSTIC VALUE OF PRE-TREATMENT SCC-AG LEVEL IN PATIENTS WITH CERVICAL CANCER
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objective The purpose of this study is to investigate the prognostic role of pre-treatment squamous cell carcinoma-related antigen (SCC-Ag)level in patients with squamous cell carcinoma of the uterine cervix. Methods In this study, we retrospectively enrolled patients with squamous cell carcinoma of the uterine cervix (FIGO stage IB to IVA) who were treated at Samsung Medical Center, Seoul, Korea, from 1996 to 2007. Results We retrospectively enrolled 788 patients. Median SCC-Ag level was 1.6 ng/mL (reference range, 0.1-362.0) in all patients. Four hundred seven out of 788 patients had elevating pre-treatment SCC-Ag level (51.6%). When we divided the cohort based on the stage (early cervical carcinoma; IB1 and IIA vs. locally advanced cervical carcinoma [LACC]; IB2 and IIB to IVA) and performed multivariate analysis, pre-treatment SCC-Ag entailed prognostic signifi cance only in LACC (progression-free survival: hazard ratio [HR], 1.007; 95% confi dential interval [CI], 1.003-1.010; overall survival: HR, 1.005; 95% CI, 1.001-1.009). Among patients who showed recurrence disease and had the result of SCC-Ag before recurrence (n=94), 79 patients (84.0%) had the elevation of SCCAg level at the time of recurrence. Conclusion Pre-treatment SCC-Ag level is an independent prognostic factor for survival in patients with LACC. Measuring pre-treatment serum SCC-Ag may be a cost-effective method to predict prognosis in patients with LACC.
Abstract
Objective The purpose of this study is to investigate the prognostic role of pre-treatment squamous cell carcinoma-related antigen (SCC-Ag)level in patients with squamous cell carcinoma of the uterine cervix. Methods In this study, we retrospectively enrolled patients with squamous cell carcinoma of the uterine cervix (FIGO stage IB to IVA) who were treated at Samsung Medical Center, Seoul, Korea, from 1996 to 2007. Results We retrospectively enrolled 788 patients. Median SCC-Ag level was 1.6 ng/mL (reference range, 0.1-362.0) in all patients. Four hundred seven out of 788 patients had elevating pre-treatment SCC-Ag level (51.6%). When we divided the cohort based on the stage (early cervical carcinoma; IB1 and IIA vs. locally advanced cervical carcinoma [LACC]; IB2 and IIB to IVA) and performed multivariate analysis, pre-treatment SCC-Ag entailed prognostic signifi cance only in LACC (progression-free survival: hazard ratio [HR], 1.007; 95% confi dential interval [CI], 1.003-1.010; overall survival: HR, 1.005; 95% CI, 1.001-1.009). Among patients who showed recurrence disease and had the result of SCC-Ag before recurrence (n=94), 79 patients (84.0%) had the elevation of SCCAg level at the time of recurrence. Conclusion Pre-treatment SCC-Ag level is an independent prognostic factor for survival in patients with LACC. Measuring pre-treatment serum SCC-Ag may be a cost-effective method to predict prognosis in patients with LACC.
참고문헌 (27)
- "GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10"[URL]
- "Global cancer facts & fi gures 2007" (2007)[URL]
- Berek JS, "Berek & Novak’s gynecology" (2007), Lippincott Williams & Wilkins
- Gien LT, "Adenocarcinoma: a unique cervical cancer", Gynecol Oncol, 116, pp.140~146 (2010)
- Davelaar EM, "A combination of serum tumor markers identifies high-risk patients with earlystage squamous cervical cancer", Tumour Biol, 29, pp.9~17 (2008)
- Maruo T, "Factors regulating SCC antigen expression in squamous cell carcinoma of the uterine cervix", Tumour Biol, 19, pp.494~504 (1998)
- Pras E, "Serum squamous cell carcinoma antigen and CYFRA 21-1 in cervical cancer treatment", Int J Radiat Oncol Biol Phys, 52, pp.23~32 (2002)
- Gadducci A, "The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature", Crit Rev Oncol Hematol, 10, pp.10~20 (2008)
- Reesink-Peters N, "Preoperative serum squamous cell carcinoma antigen levels in clinical decision making for patients with early-stage cervical cancer", J Clin Oncol, 23, pp.1455~1462 (2005)
- Rose PG, "Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer", N Engl J Med, 340, pp.1144~1153 (1999)
- Peters WA 3rd, "Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix", J Clin Oncol, 18, pp.1606~1613 (2000)
- Choi CH, "A Matched-Case Comparison to Explore the Role of Consolidation Chemotherapy After Concurrent Chemoradiation in Cervical Cancer", Int J Radiat Oncol Biol Phys (2010)[DOI]
- Pecorelli S, "Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium", Int J Gynaecol Obstet, 105, pp.103~104 (2009)
- Kidd EA, "Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis", J Clin Oncol, 28, pp.2108~2113 (2010)
- Kato H, "Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma", Cancer, 40, pp.1621~1628 (1977)
- Gadducci A, "Biochemical prognostic factors and risk of relapses in patients with cervical cancer", Gynecol Oncol, 107, pp.23~26 (2007)
- van de Lande J, "SCC-Ag, lymph node metastases and sentinel node procedure in early stage squamous cell cervical cancer", Gynecol Oncol, 112, pp.119~125 (2009)
- Gaarenstroom KN, "Clinical value of pretreatment serum Cyfra 21-1, tissue polypeptide antigen, and squamous cell carcinoma antigen levels in patients with cervical cancer", Cancer, 76, pp.807~813 (1995)
- Takeda M, "Preoperative serum SCC, CA125, and CA19-9 levels and lymph node status in squamous cell carcinoma of the uterine cervix", Acta Obstet Gynecol Scand, 81, pp.451~457 (2002)
- Hong JH, "Risk stratifi cation of patients with advanced squamous cell carcinoma of cervix treated by radiotherapy alone", Int J Radiat Oncol Biol Phys, 63, pp.492~499 (2005)
- Hong JH, "The prognostic signifi cance of pre- and posttreatment SCC levels in patients with squamous cell carcinoma of the cervix treated by radiotherapy", Int J Radiat Oncol Biol Phys, 41, pp.823~830 (1998)
- Ferrandina G, "Squamous cell carcinoma antigen in patients with locally advanced cervical carcinoma undergoing preoperative radiochemotherapy: association with pathological response to treatment and clinical outcome", Oncology, 74, pp.42~49 (2008)
- Yalman D, "Prognostic factors in defi nitive radiotherapy of uterine cervical cancer", Eur J Gynaecol Oncol, 24, pp.309~314 (2003)
- Torre GC, "SCC antigen in malignant and nonmalignant squa mous lesions", Tumour Biol, 19, pp.517~526 (1998)
- Lomnytska MI, "Differential expression of ANXA6, HSP27, PRDX2, NCF2, and TPM4 during uterine cervix carcinogenesis: diagnostic and prognostic value", Br J Cancer, 104, pp.110~119 (2011)
- Min L, "Clinicopathological and prognostic signifi cance of Bmi-1 expression in human cervical cancer", Acta Obstet Gynecol Scand, 90, pp.737~745 (2011)
- Porika M, "Evaluation of serum human telomerase reverse transcriptase as a novel marker for cervical cancer", Int J Biol Markers, 26, pp.22~26 (2011)